Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight
The increasing diagnosed prevalence, and the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for RVO patients will drive the retinal vein occlusion market growth in the forecast period (2023–2032).
New York, USA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- *Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight *
*The increasing diagnosed prevalence, and the development of well-designed, randomized, controlled non-crossover trials with the potential benefits for RVO patients will drive the retinal vein occlusion market growth in the forecast period (2023–2032).*
DelveInsight’s *Retinal Vein Occlusion Market Insights* report includes a comprehensive understanding of current treatment practices, retinal vein occlusion emerging drugs, market share of individual therapies, and current and forecasted retinal vein occlusion market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
*Key Takeaways from the Retinal Vein Occlusion Market Report*
· As per DelveInsight’s analysis, the retinal vein occlusion market size was found to be *USD 2.3 billion* in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, in the year 2021, the total prevalent cases of retinal vein occlusion were approximately *2.7 million* cases in the 7MM, which are expected to increase by 2032 at the *CAGR of 1.0%* during the study period (2019–2032).
· Leading retinal vein occlusion companies such as *Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Roche, Chugai Pharmaceuticals, *and others are developing novel retinal vein occlusion drugs that can be available in the retinal vein occlusion market in the coming years.
· Some of the key therapies for retinal vein occlusion treatment include *TLC399 (ProDex), AR-1105, GB-102 (sunitinib/sunitinib malate), ONS-5010/Lytenava(bevacizumab-vikg), KSI-301, Vabysmo (faricimab)**, *and others.
Discover which therapies are expected to grab the major retinal vein occlusion market share @ *Retinal Vein Occlusion Market Report*
*Retinal Vein Occlusion Overview*
Retinal vein occlusion (RVO) stands as the second most prevalent retinal vascular disorder, following diabetic retinopathy. It results from an obstruction in the retinal venous system due to thrombus formation and can affect the central, hemi-central, or branch retinal vein. The primary causative factor is often compression by nearby atherosclerotic retinal arteries. Additionally, other potential causes include external compression or vein wall diseases like vasculitis.
The main indicator is a sudden alteration in vision. This might manifest as blurred vision or a partial or complete loss of sight. The continuous presence of bruising and swelling in the macula is linked to a permanent loss of central vision. This swelling results from damaged blood vessels that release fluid. Typically, these symptoms manifest in one eye, are frequently painless, and can be either temporary or permanent, contingent upon the patient's promptness in seeking treatment and their overall health.
When examining a patient with RVO, it is crucial to undertake a comprehensive evaluation of their adult medical eye health, with particular attention to elements related to retinal vascular diseases. Various diagnostic tests, including Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA), are employed for RVO diagnosis. Additionally, systemic evaluation is often carried out in patients with CRVO, and the direction of this evaluation is determined by the patient's age, concurrent risk factors, and medical history.
*Retinal Vein Occlusion Epidemiology Segmentation*
The retinal vein occlusion epidemiology section provides insights into the historical and current retinal vein occlusion patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The *retinal vein occlusion market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Total Retinal Vein Occlusion Prevalent Cases
· Total Retinal Vein Occlusion Diagnosed Prevalent Cases
· Total Retinal Vein Occlusion Gender-specific Diagnosed Prevalent Cases
· Total Retinal Vein Occlusion Age-specific Diagnosed Prevalent Cases
· Retinal Vein Occlusion Type-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving retinal vein occlusion epidemiology trends @ *Retinal Vein Occlusion Epidemiological Insights*
*Retinal Vein Occlusion Treatment Market *
Currently, there is no known remedy to reverse RVO. Individuals afflicted with this condition typically experience enduring alterations in their vision. The primary objective of available treatments is to maintain vision stability by sealing off leaking blood vessels. Key treatments for RVO encompass intravitreal injections of drugs that target vascular endothelial growth factors (VEGF) or corticosteroids designed to combat the growth factors or inflammatory elements that contribute to macular edema. In certain cases where anti-VEGF drugs prove ineffective, intraocular steroid injections may be considered, though they may carry some side effects like increased eye pressure and cataract progression. In challenging situations, laser therapy might be employed in conjunction with anti-VEGF treatment. Pan-retinal laser photocoagulation (PRP) or focal photocoagulation effectively manage neovascularization, preventing neovascularization-related complications in both BRVO and CRVO. Meanwhile, macular laser photocoagulation can address non-ischemic macular edema either as a standalone treatment or in combination with other anti-VEGF or anti-inflammatory medications.
The European Society of Retina Specialists Guidelines suggest that although laser treatment can enhance visual function in cases of macular edema secondary to BRVO, it should be considered a second-line option due to the presence of anti-VEGF therapy alternatives. The US FDA has sanctioned three products for managing macular edema associated with RVO, namely *Lucentis (ranibizumab, Roche), Eylea (aflibercept, Regeneron), and Ozurdex (dexamethasone intravitreal implant, AbbVie).*
Learn more about the FDA-approved drugs for retinal vein occlusion @ *Drugs for* *Retinal Vein Occlusion Treatment** *
*Key Retinal Vein Occlusion Therapies and Companies*
· TLC399 (ProDex): Taiwan Liposome Company
· AR-1105: Aerie Pharmaceuticals
· GB-102 (sunitinib/sunitinib malate): Graybug Vision
· ONS-5010/Lytenava(bevacizumab-vikg): Outlook Therapeutics
· KSI-301: Kodiak Sciences Inc
· Vabysmo (faricimab): Roche/Chugai Pharmaceuticals
To know more about retinal vein occlusion clinical trials, visit @ *Retinal Vein Occlusion Treatment Drugs** *
*Retinal Vein Occlusion Market Dynamics*
The dynamics of the retinal vein occlusion market are anticipated to change in the coming years. Currently, *anti-VEGF drugs* are the dominant choice for treating RVO, and this trend is expected to continue in the forecast period. The *increasing prevalence of diabetes, lifestyle changes, and a rising incidence of glaucoma*, among other factors, are driving the growing use of anti-VEGF drugs in RVO treatment. The *expanding elderly population and heightened awareness* of eye disorders are expected to increase RVO cases, thereby creating opportunities for new treatment options. Companies can seize the opportunity to meet the *unmet needs of RVO patients* by offering more durable responses, reduced clinic visits, and improved safety profiles.
However, several factors may impede the growth of the retinal vein occlusion market. Retinal vein occlusion predominantly impacts individuals *aged 55 and older*, particularly those with underlying high-risk conditions such as *diabetes and hypertension*. These comorbidities can complicate the treatment approach. Moreover, most *currently approved medications* do not effectively restore visual function, nor do they directly address the underlying vein blockage. The impending expiration of patents for branded drugs, coupled with the market entry of *cost-effective generics and biosimilars*, is expected to impede market growth significantly. Additionally, the intricate nature of the disease and the presence of *anti-VEGF therapies* make it challenging for companies to demonstrate the superior efficacy and added benefits of their drugs compared to existing treatments. For instance, *Clearside Biomedical's product Xipere (Suprachoroidal CLS-TA)* failed to meet primary endpoints in the *Phase III SAPPHIRE trial*.
*Retinal Vein Occlusion Report Metrics* *Details*
Study Period 2019–2032
Retinal Vein Occlusion Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Retinal Vein Occlusion Market Size in 2021 USD 2.3 Billion
Key Retinal Vein Occlusion Companies Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Roche, Chugai Pharmaceuticals, and others
Key Retinal Vein Occlusion Therapies TLC399 (ProDex), AR-1105, GB-102 (sunitinib/sunitinib malate), ONS-5010/Lytenava(bevacizumab-vikg), KSI-301, Vabysmo (faricimab), and others
*Scope of the **Retinal Vein Occlusion** Market Report*
· *Therapeutic Assessment: *Retinal Vein Occlusion current marketed and emerging therapies
· *Retinal Vein Occlusion* *Market Dynamics:* Attribute Analysis of Emerging Retinal Vein Occlusion Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Retinal Vein Occlusion Market Access and Reimbursement*
Discover more about retinal vein occlusion drugs in development @ *Retinal Vein Occlusion Clinical Trials*
*Table of Contents*
1. Retinal Vein Occlusion Market Key Insights
2. Retinal Vein Occlusion Market Report Introduction
3. Retinal Vein Occlusion Market Overview at a Glance
4. Retinal Vein Occlusion Market Executive Summary
5. Disease Background and Overview
6. Retinal Vein Occlusion Treatment and Management
7. Retinal Vein Occlusion Epidemiology and Patient Population
8. Patient Journey
9. Retinal Vein Occlusion Marketed Drugs
10. Retinal Vein Occlusion Emerging Drugs
11. Seven Major Retinal Vein Occlusion Market Analysis
12. Retinal Vein Occlusion Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Related Reports*
*Retinal Vein Occlusion Epidemiology Forecast*
*Retinal Vein Occlusion Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted retinal vein occlusion epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*Retinal Vein Occlusion Pipeline*
*Retinal Vein Occlusion Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key retinal vein occlusion companies, including *Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, *among others.
*Central Retinal Vein Occlusion Pipeline*
*Central Retinal Vein Occlusion Pipeline Insight – 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key central retinal vein occlusion companies, including* 3SBio, Gene Signal, Celon pharma, The Emmes Company, LLC, *among others.
*Central Retinal Vein Occlusion Market*
*Central Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast **– 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key central retinal vein occlusion companies, including* 3SBio, Gene Signal, Celon pharma, The Emmes Company, LLC, *among others.
*Central Retinal Vein Occlusion Epidemiology Forecast*
*Central Retinal Vein Occlusion Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted central retinal vein occlusion epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*Other Trending Reports*
*Digestive System Fistula Market** | **Dementia With Diabetes Market** | **Leber's Hereditary Optic Neuropathy Market** | **Pecoma Market** | **Adamantinoma Market** | **Pegfilgrastim Biosimilar Insight** | **Functional Constipation Market** | **DDR Defective Tumors Market** | **Nephrotic Syndrome Pipeline** | **Pelizaeus-Merzbacher Disease Market** | **Hepatic Impairment Market** | **Primary Ciliary Dyskinesia Market** | **Surgical Bleeding Market** | Radiotherapy-Induced** Oral Mucositis Market** | **Relapsed Chronic Lymphocytic Leukemia CLL Market** | **Galactosemia Market** | **Glabellar Lines Market** | **Homozygous Familial Hypercholesterolemia Market** | **HR Positive/ HER2 Negative Breast Cancer Market** | **Lebers Hereditary Optic Neuropathy LHON Market** | **Nonalcoholic Fatty Liver Disease NAFLD Market** | **Orthotic Devices Market** | **Polypoidal Choroidal Vasculopathy Market** | **Sporadic Inclusion Body Myositis Market** | **Acid Sphingomyelinase Deficiency ASMD Market** | **B-Cell Chronic Lymphocytic Leukemia Market** | **Coccidioidomycosis Market** | **Granulomatosis With Polyangiitis Market** | **Malignant Pleural Mesothelioma Market** | **Nocturnal Enuresis Market** | **Postmyocardial Infarction Syndrome Market** | **Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market** | **Typhoid Fever Market** | **Ventricular Dysfunction Market** | **Burkitt Lymphoma Market** | **Chronic Progressive Multiple Sclerosis Market** | **Emesis Market** | **Fenebrutinib Market** | **Gastric Neuroendocrine Tumors Market** | **Juvenile Rheumatoid Arthritis Market** | **Persistent Epithelial Defects Market** | **Post-Polycythemia Vera Myelofibrosis Market** | **Primary Mediastinal Large B-Cell Lymphoma Market** | **Spinocerebellar Ataxias Market** | **Systemic Inflammatory Response Syndrome Market** | **Triple Negative Breast Cancer Market** | **Visceral Pain Associated With GI Disorders Market** | **Adrenal Cortex Neoplasms Market** | **Adrenal Insufficiency Market** | **Artificial Lung Devices Market** | **Atopic Keratoconjunctivitis AKC Market** | **Autonomic Dysfunction Market** | **Bradycardia Treatment Devices Market** | **Bullous Pemphigoid Market** | **Cone Rod Dystrophy Market** | **Cutaneous Lupus Erythematosus Market** | **Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market** | **Dermal Regeneration Matrix Market** | **Heart Pump Devices Market** | **Hemiplegia Market** | **Hepatic Impairement Market** | **Immunologic Deficiency Syndrome Market** | **Implantable Infusion Pump Market** | **Menorrhalgia Market Size** | **Myocarditis Market** | **Myopia Treatment Devices Market** | **Ocular Hypertension Market *
*Related Healthcare Services*
*Healthcare Consulting*
*Healthcare Competitive Intelligence Services*
*Healthcare Asset Prioritization Services*
*About DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*
*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com